ライフサイエンスコーパス: paroxetine

1 sma was made (single oral dose of 37.5 mg of paroxetine).

2 very rate < 0.05 associated with response to paroxetine.

3 rval, 1.4 to 4.2) that among those receiving paroxetine.

4 ceived two years of maintenance therapy with paroxetine.

5 hodology was applied to the synthesis of (-)-Paroxetine.

6 d is reversed by propranolol, clonidine, and paroxetine.

7 with efficacy and tolerability comparable to paroxetine.

8 men were less likely to discontinue low-dose paroxetine.

9 hydrochloride ER and 46.0 mg (SD, 7.9 mg) of paroxetine.

10 xan 80 mg was observed to be same as that of paroxetine.

11 nescent female Sprague-Dawley rats using [3H]paroxetine.

12 bated with the high-affinity SERT antagonist paroxetine.

13 treatment with a maximally tolerated dose of paroxetine.

14 reast-feeding during maternal treatment with paroxetine.

15 re subject to site differences than those of paroxetine.

16 terans with PTSD were treated with the SSRI, paroxetine.

17 und to the antidepressants (S)-citalopram or paroxetine.

18 commercial serotonin reuptake inhibitor (-)-paroxetine.

19 jection of clorgyline combined with the SSRI paroxetine.

20 elective synthesis of the antidepressant (-)-paroxetine.

21 responsive to prophylactic administration of paroxetine.

22 (1.41, 1.35, 1.30, and 1.27, respectively), paroxetine (1.35, 1.30, 1.27, and 1.22, respectively), a

23 xan 80 mg, placebo [-2.20 (-4.64, 0.24)] and paroxetine [-1.24 (-5.34, 2.85)].

24 trolled trial to investigate the efficacy of paroxetine 10 mg and 20 mg compared to placebo in reduci

25 Women were randomly assigned to 4 weeks of paroxetine 10 mg or 20 mg followed by placebo for 4 week

26 4 weeks, or placebo for 4 weeks followed by paroxetine 10 mg or 20 mg for 4 weeks.

27 Paroxetine 10 mg reduced hot flash frequency and composi

28 Paroxetine 10 mg was associated with a significant impro

29 le patients were randomized (1:1) to receive paroxetine (10-50 mg/d) or placebo.

30 ine 104, maprotiline 109, nortriptyline 114, paroxetine 118, sertraline 124, suloctidil 125, and terf

31 nt as usual (psychotherapy, $976 [SD, $984]; paroxetine, $1252 [SD, $1616]; and treatment as usual, $

32 h the selective serotonin reuptake inhibitor paroxetine; 2 psychiatrist visits and 2 telephone calls

33 Paroxetine 20 mg reduced hot flash frequency and composi

34 n compared to silexan 160 mg, silexan 80 mg, paroxetine 20 mg, and placebo.

35 h the selective serotonin reuptake inhibitor paroxetine (20 mg/d), the patients with depression were

36 venlafaxine hydrochloride ER (75-225 mg/d), paroxetine (20-50 mg/d), or placebo for 12 weeks or less

37 ndomly assigned to 8 weeks of treatment with paroxetine, 20 or 40 mg/day, or placebo.

38 ntidepressants (amitriptyline, 304 ng/L, and paroxetine, 26 ng/L), and two anthelmintic agents (meben

39 omponent scores, 4.7 [2.03] for those taking paroxetine; 4.7 [1.96] for the PST-PC treatment; P =.02

40 were statistically significantly greater for paroxetine (77.6% response [125/161]) than for placebo (

41 mpared the widely prescribed antidepressants paroxetine (a selective serotonin reuptake inhibitor [SS

42 Treatment of wild type mice with paroxetine, a chemical inhibitor of SERT, also resulted

43 Follow-up studies focused on paroxetine, a clinically used antidepressant compound th

44 his randomized clinical trial tested whether paroxetine, a selective serotonin reuptake inhibitor ant

45 g kinase 1 (ROCK1) inhibitor, the other from paroxetine, a selective serotonin-reuptake inhibitor.

46 We report that administration of paroxetine, a widely prescribed antidepressant drug that

47 sions appear less responsive to prophylactic paroxetine administration.

48 ity SSRIs, racemic citalopram ((RS)-CIT) and paroxetine, affect the outgrowth of embryonic thalamic a

49 to 56-fold) whilst ibogaine, imipramine and paroxetine all bound with lower affinity (up to 90-fold)

50 Paroxetine also improved SBP response to exercise.

51 euticals, such as treatments for depression (paroxetine, amitifadine), diabetes (gliclazide), leukaem

52 ared prolonged exposure therapy (a CBT) plus paroxetine (an SSRI) with prolonged exposure plus placeb

53 , SERT Met172 mice maintained sensitivity to paroxetine, an antidepressant that is unaffected by the

54 ctility at 20-fold lower concentrations than paroxetine, an inhibitor with more modest selectivity fo

55 The indazole-paroxetine analogs were indeed more potent than their re

56 f GRK2 compared with previous complexes with paroxetine analogs.

57 aN72/DeltaC13 and ts2-inactive SERT bound to paroxetine analogues using single-particle cryo-EM and x

58 rse events were infrequent (5.5% [9/163] for paroxetine and 1.3% [2/156] for placebo).

59 ed 20 patients to receive the antidepressant paroxetine and 20 to receive placebo.

60 A total of 244 patients treated with paroxetine and 235 patients treated with placebo provide

61 t in cardiomyocyte contractility assays over paroxetine and a plasma concentration higher than its IC

62 We directly measured the K(D) for paroxetine and assessed its mechanism of inhibition for

63 We treated DBA/2J mice for 28 days with paroxetine and assessed their behavioral response with t

64 3 for the interaction between treatment with paroxetine and baseline severity of medical illness).

65 Likewise, paroxetine and benzodiazepines were effective but also p

66 .85) and -9.6% per year (P = .21) during the paroxetine and black box warning study periods, respecti

67 The paroxetine and black box warnings had modest and relativ

68 psychotherapy, 37 percent of those receiving paroxetine and clinical-management sessions, 68 percent

69 ssociated with better response to two SSRIs (paroxetine and fluoxetine).

70 However, both paroxetine and imipramine were superior to placebo for p

71 is study compared the efficacy and safety of paroxetine and imipramine with that of placebo in the tr

72 r 2005 rates for all antidepressants, except paroxetine and imipramine, started to rise again.

73 changes with 2 distinct forms of treatment (paroxetine and interpersonal psychotherapy).

74 rovide mutually consistent insights into how paroxetine and its analogues bind to the central substra

75 We tested the efficacy of maintenance paroxetine and monthly interpersonal psychotherapy in pa

76 is demonstrated via formal synthesis of (-)-paroxetine and other bioactive molecules.

77 For the paroxetine and placebo groups, the 6 visits over 11 week

78 For minor depression, both paroxetine and PST-PC improved mental health functioning

79 who had a response to initial treatment with paroxetine and psychotherapy were less likely to have re

80 g patients with a response to treatment with paroxetine and psychotherapy, 116 were randomly assigned

81 ears in 35 percent of the patients receiving paroxetine and psychotherapy, 37 percent of those receiv

82 x that now were significantly enhanced under paroxetine and reduced under bupropion.

83 13 exposed subjects) and between the use of paroxetine and right ventricular outflow tract obstructi

84 o significant association between the use of paroxetine and right ventricular outflow tract obstructi

85 comparisons showed possible associations of paroxetine and sertraline with other specific defects.

86 curring at an incidence of 5% or greater for paroxetine and twice that for placebo were insomnia (14.

87 Published results from one trial of paroxetine and two trials of sertraline suggest equivoca

88 own improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with

89 hepatotoxicity are citalopram, escitalopram, paroxetine, and fluvoxamine.

90 Nortriptyline, paroxetine, and sertraline may be preferred choices in b

91 Nortriptyline, paroxetine, and sertraline usually produce undetectable

92 SSRIs; citalopram, escitalopram, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine

93 s with malignant melanoma, pretreatment with paroxetine appears to be an effective strategy for minim

94 Paroxetine appears to have a specific pharmacological ef

95 Doses of 20 and 40 mg/day of paroxetine are effective and well tolerated in the treat

96 encies of the antidepressants tianeptine and paroxetine are unchanged.

97 identifies a novel pharmacological action of paroxetine as a protector of endothelial cells against h

98 (HPLC-MS/MS) assay has been validated using paroxetine as a tool compound (range 0.2-200 ng/mL human

99 identified the serotonin reuptake inhibitor paroxetine as an inhibitor of G protein-coupled receptor

100 of the observed effect, with albendazole and paroxetine as the predominant contributors (49% and 49%,

101 ted after 10 days of maternal treatment with paroxetine at a stable daily dose (10-50 mg/day).

102 Paroxetine attenuated motor dysfunction and body weight

103 Paroxetine augmented systolic blood pressure (SBP) durin

104 Time of day influenced [3H]paroxetine binding in the SCN and the paraventricular th

105 The density of specific [3H]paroxetine binding in various brain regions was compared

106 ng independently increased the number of [3H]paroxetine binding sites.

107 nly region that displayed a reduction in [3H]paroxetine binding with age was the suprachiasmatic nucl

108 n contrast, Cl(-) did not enhance cocaine or paroxetine binding.

109 depressants, particularly those who received paroxetine, but was reduced in older adults.

110 of: (1) switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20-40 mg); (2) sw

111 cal trials of nortriptyline hydrochloride or paroxetine combined with interpersonal psychotherapy (N

112 provement score of 1) was 47.8% (77/161) for paroxetine compared with 14.9% (23/154) for placebo.

113 ater baseline suicidal ideation treated with paroxetine compared with bupropion appeared to experienc

114 mong users of amitriptyline, fluoxetine, and paroxetine compared with the risk among users of dothiep

115 fluoxetine, and 1.29 (95% CI, 0.97-1.70) for paroxetine compared with those using dothiepin.

116 t gradient effect was observed, with greater paroxetine concentrations found in later portions of bre

117 Breast milk paroxetine concentrations were highly variable (2-101 ng

118 ter than 85% inhibition) of control at these paroxetine concentrations.

119 We synthesized enantiopure analogues of paroxetine containing either bromine or iodine instead o

120 placebo or receive 12.5 mg/d or 25.0 mg/d of paroxetine CR (in a 1:1:1 ratio) for 6 weeks.

121 ean reduction, 3.2) for those in the 25-mg/d paroxetine CR groups and from 6.6 to 4.8 (mean reduction

122 .5-mg/d and 64.6% for those in the 25.0-mg/d paroxetine CR groups compared with 37.8% for those in th

123 Paroxetine CR may be an effective and acceptable alterna

124 ly significantly greater for those receiving paroxetine CR than for those receiving placebo.

125 l, -6.8 to -0.4; P =.03) comparing 25.0-mg/d paroxetine CR with placebo.

126 - 8.1 to -1.3; P =.007) comparing 12.5-mg/d paroxetine CR with placebo; and -3.6 (95% confidence int

127 ive 12.5 mg/d and 58 to receive 25.0 mg/d of paroxetine CR.

128 Paroxetine, currently classified as a selective 5-HT reu

129 ast milk was demonstrated, although maternal paroxetine daily dose reliably predicted both trough and

130 Paroxetine decreased norepinephrine uptake to 73% of con

131 new inhibitor, CCG258747, which is based on paroxetine, demonstrates increased potency against the G

132 potency when substituted for benzodioxole in paroxetine derivatives.

133 Paroxetine did not show statistical superiority to desip

134 lthough all patient groups received the same paroxetine dose for the same duration, regional metaboli

135 ol t.i.d. or placebo for 4 weeks to a steady paroxetine dose.

136 Pretreatment with paroxetine dramatically altered the metabolism and kinet

137 SSRIs citalopram, sertraline and especially paroxetine dropped dramatically after 2002, while rates

138 After 5 d of paroxetine, EMGgg activity increased significantly withi

139 No clear time course of paroxetine excretion into breast milk was demonstrated,

140 Paroxetine exhibits up to 50-fold selectivity for GRK2 v

141 atients treated with prolonged exposure plus paroxetine experienced significantly greater improvement

142 onin reuptake inhibitors (SSRIs: citalopram, paroxetine, fluoxetine and sertraline) in a retrospectiv

143 The SSRI antidepressants paroxetine, fluoxetine, and sertraline were similar in e

144 ansporter affinity, all of which were SSRIs (paroxetine, fluoxetine, and sertraline).

145 ctive serotonin reuptake inhibitors (SSRIs) (paroxetine, fluoxetine, fluvoxamine, and sertraline) and

146 islets or Min6 beta cell line with the SSRIs paroxetine, fluoxetine, or sertraline inhibited insulin-

147 o were all then treated with 30-60 mg/day of paroxetine for 8-12 weeks.

148 Our results suggest that the selectivity of paroxetine for GRK2 largely reflects its lower affinity

149 s study evaluated the efficacy and safety of paroxetine for the treatment of patients with chronic po

150 ression developed in 2 of 18 patients in the paroxetine group (11 percent) and 9 of 20 patients in th

151 fore 12 weeks in 1 of the 20 patients in the paroxetine group (5 percent), as compared with 7 patient

152 d to psychotherapy and 43 of 86 (50%) of the paroxetine group completed the full course of treatment.

153 inical effects with brain drug levels in the paroxetine group suggests that relationships between dru

154 Summary score at 9 months was + 15.8 in the paroxetine group, + 15.1 in the fluoxetine group, and +

155 ificantly greater for the venlafaxine ER and paroxetine groups (58.6% and 62.5%, respectively) vs the

156 30% and 36% of patients in the 20- and 40-mg paroxetine groups, respectively, compared with 20% given

157 ty scale were significantly greater for both paroxetine groups.

158 order of potency: sertraline > fluoxetine > paroxetine > fluvoxamine > citalopram.

159 Furthermore, we show that compounds based on paroxetine had much better cell permeability than those

160 Paroxetine had no influence on fatigue in patients recei

161 c test compounds at exposure pH (bromoxynil, paroxetine), however, the extent and the speed of uptake

162 aining complexes confirmed that the indazole-paroxetine hybrids form stronger interactions with the h

163 e effect of the serotonin reuptake inhibitor paroxetine hydrochloride (Paxil, SmithKline Beecham) on

164 mly assigned to receive either 20 mg of oral paroxetine hydrochloride daily or placebo for 8 weeks.

165 d Drug Administration (FDA) recommended that paroxetine hydrochloride not be used to treat young peop

166 s were randomly assigned to pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride) (n

167 tpatients under protocolized conditions with paroxetine hydrochloride or nortriptyline hydrochloride,

168 = 0.98 (95% confidence interval, 0.63-1.51); paroxetine hydrochloride, hazard ratio = 1.02 (95% confi

169 lective serotonin reuptake inhibitor (SSRI), paroxetine hydrochloride, may increase genioglossal elec

170 e, mirtazapine, nortriptyline hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and

171 re and after 8 to 12 weeks of treatment with paroxetine hydrochloride.

172 ents with severe IBS, both psychotherapy and paroxetine improve health-related quality of life at no

173 For dysthymia, paroxetine improved mental health functioning vs placebo

174 e behavioral effects of both desipramine and paroxetine in Dbh(-/-) mice, thus demonstrating that the

175 The low concentrations of paroxetine in infant serum and lack of any observable ad

176 hed that (1) fluoxetine was more potent than paroxetine in inhibiting agonist-activated Ca(2+) influx

177 However, the binding site and orientation of paroxetine in SERT remain controversial.

178 serotonin-selective reuptake inhibiting drug paroxetine in the incubation medium.

179 tribute to the broad therapeutic efficacy of paroxetine in the treatment of depression, panic disorde

180 assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disor

181 sovagal syncope (propranolol, clonidine, and paroxetine) in a double-blind crossover study.

182 ival analysis showed discontinuations due to paroxetine-induced side effects were strongly associated

183 5-HT, d-amphetamine, cocaine, and paroxetine inhibit transport more potently at lower expr

184 The study examined whether paroxetine inhibits the human norepinephrine transporter

185 han pharmacokinetic variation in determining paroxetine intolerance.

186 Paroxetine is an effective treatment for hot flashes in

187 Paroxetine is an effective, generally well-tolerated tre

188 This study demonstrates that paroxetine is an efficacious and well-tolerated treatmen

189 ogen bond formed by the benzodioxole ring of paroxetine is better accommodated by GRKs.

190 ng those starting the newest antidepressant, paroxetine, is of a magnitude that could readily be due

191 elease venlafaxine was more efficacious than paroxetine, lithium augmentation more than phenelzine, a

192 ules versus other comparators (i.e., placebo/paroxetine/lorazepam).

193 Paroxetine maintained the ability of vascular rings to r

194 in controls but declined significantly after paroxetine monotherapy to levels comparable with those o

195 moderate to severe MDD randomized to receive paroxetine (n = 120), placebo (n = 60), or cognitive the

196 of mirtazapine (n = 124) or 20 to 40 mg/d of paroxetine (n = 122).

197 Patients were randomly assigned to receive paroxetine (n = 137) or placebo (n = 140), starting at 1

198 Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertralin

199 g/day of paroxetine (N=183), or 40 mg/day of paroxetine (N=182) for 12 weeks.

200 signed to take placebo (N=186), 20 mg/day of paroxetine (N=183), or 40 mg/day of paroxetine (N=182) f

201 t with prolonged exposure (10 sessions) plus paroxetine (N=19) or prolonged exposure plus placebo (N=

202 ha and ribavirin received the antidepressant paroxetine (n=28) or a placebo (n=33).

203 se, were randomly assigned to treatment with paroxetine (N=35), imipramine (N=39), or placebo (N=43)

204 e-blind, randomized, clinical pilot trial of paroxetine (N=36) or bupropion (N=38) in DSM IV major de

205 cluded in the intention-to-treat population (paroxetine, n = 163; placebo, n = 156).

206 uble-blind conditions to one of four groups: paroxetine+naltrexone; paroxetine+placebo; desipramine+n

207 the determination of whether this effect of paroxetine on platelet function is caused by a direct ef

208 ior to placebo for augmenting the effects of paroxetine on social anxiety symptoms.

209 model selection showed modest advantages for paroxetine on: (1) mHDRS-17 (p=0.02); and (2) in a separ

210 subfamily selectivities and with either the paroxetine or GSK180736A scaffold to block internalizati

211 milies of GRK inhibitors based on either the paroxetine or GSK180736A scaffold.

212 , subjects with MDD were treated with either paroxetine or interpersonal psychotherapy (based on pati

213 four maintenance-treatment programs (either paroxetine or placebo combined with either monthly psych

214 in reuptake inhibitor (SSRI) antidepressant, paroxetine, or routine care by a gastroenterologist and

215 regnant women taking citalopram, fluoxetine, paroxetine, or sertraline participated.

216 The advantage of paroxetine over placebo in antidepressant efficacy was n

217 rdiac disease) received greater benefit from paroxetine (P=0.03 for the interaction between treatment

218 Lithium and the antidepressant (AD) paroxetine (PAR) functionally synergize with FKBP51, as

219 e with the antidepressants reboxetine (REB), paroxetine (PAROX) and clomipramine (CLOM) on extracellu

220 Paroxetine patients showed greater (difference in mean [

221 ptake inhibitors (SSRI)-fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa)-substantiall

222 oactive agents, including the antidepressant paroxetine (Paxil), the most potent selective serotonin

223 the antidepressants sertraline (Zoloft) and paroxetine (Paxil).

224 o one of four groups: paroxetine+naltrexone; paroxetine+placebo; desipramine+naltrexone; desipramine+

225 uate response to standardized treatment with paroxetine plus interpersonal psychotherapy.

226 Initial treatment with paroxetine plus prolonged exposure was more efficacious

227 % (SD=17%) of the brain fluorine signal from paroxetine (plus fluorinated metabolites).

228 and a baboon with reduced SERT availability (paroxetine pretreatment).

229 antidepressant, serotonin reuptake inhibitor paroxetine (PX), recapitulated the effects of GRK2 silen

230 21) decreased the cerebrocortical binding of paroxetine (PXT), a marker for the serotonin (5HT) trans

231 tinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine.

232 tine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine.

233 Paroxetine reduced hyperglycemia-induced mitochondrial R

234 l trial we have previously demonstrated that paroxetine reduces hot flashes.

235 Patients taking paroxetine reported 6.8 times as much change on neurotic

236 Patients who took paroxetine reported greater personality change than plac

237 8% of the patients receiving 20 and 40 mg of paroxetine, respectively, compared with a 46% response r

238 reatment predicted lower relapse rates among paroxetine responders (P = .003) but not among cognitive

239 Compared to imipramine, paroxetine resulted in a lower incidence of adverse even

240 Paroxetine reversed paradoxical vascular responses durin

241 This study validates the paroxetine scaffold as the most effective for GRK inhibi

242 [125I]iodocyanopindolol ([125I]ICYP) and [3H]paroxetine, selective radioligands for the 5-HT(1B) rece

243 derstand the molecular mechanisms underlying paroxetine selectivity among GRKs.

244 olonging potential (fluoxetine, fluvoxamine, paroxetine, sertraline).

245 ine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine.

246 concentrations up to 50 microM, fluoxetine, paroxetine, sertraline, norfluoxetine, carbamazepine, cl

247 served were the antidepressants (citalopram, paroxetine, sertraline, venlafaxine, and bupropion, and

248 ndicated that S allele carriers treated with paroxetine showed a small impairment in antidepressant r

249 Paroxetine showed moderate benefit for depressive sympto

250 Our data suggest that the orientation of paroxetine, specifically its fluorophenyl ring, in SERT'

251 Under paroxetine, subjects showed significantly decreased acti

252 depressant medication intervention (trial of paroxetine switched to buproprion, if lack of response)

253 nificantly greater improvement was seen with paroxetine than placebo.

254 ext, we designed a benzolactam derivative of paroxetine that has optimized interactions with the hing

255 ects study design and administering the SSRI paroxetine, the dopamine/norepinephrine reuptake inhibit

256 The lowest ratios were for sertraline and paroxetine; the highest were for citalopram and fluoxeti

257 ture-based drug design approach, we modified paroxetine to generate a small compound library.

258 The ability of paroxetine to improve hyperglycemic endothelial cell inj

259 number of patients needed to be treated with paroxetine to prevent one recurrence was 4 (95 percent c

260 melanogaster dopamine transporter and docked paroxetine to these models.

261 =20 were randomly assigned to treatment with paroxetine (to 60 mg/day) or desipramine (to 30 mg/day)

262 udy compared the serotonin uptake inhibitor, paroxetine, to the norepinephrine uptake inhibitor, desi

263 d decreases in normalized prefrontal cortex (paroxetine-treated bilaterally and interpersonal psychot

264 Paroxetine-treated long-time floating (PLF) and paroxeti

265 lar pathways and biosignatures that stratify paroxetine-treated mouse sub-groups.

266 Paroxetine-treated patients in both dose groups demonstr

267 Side effect severity in paroxetine-treated patients with the C/C genotype was al

268 Such effects were not observed in paroxetine-treated SERT (-/-) mice.

269 oxetine-treated long-time floating (PLF) and paroxetine-treated short-time floating (PSF) groups were

270 After treatment, paroxetine-treated subjects had a greater mean decrease

271 Among paroxetine-treated subjects, S allele carriers experienc

272 : SAD=15, controls=17) and following 8-weeks paroxetine treatment (N: SAD=12, untreated controls=7).

273 reductions may, however, not be specific to paroxetine treatment and could be due to a more general

274 er status, and was significantly superior to paroxetine treatment at weeks 1 and 2 for the Social Pho

275 tom dimension was significantly lower in the paroxetine treatment group (p=0.04); severity of the neu

276 sion symptom dimension is more responsive to paroxetine treatment in individuals undergoing concomita

277 es in pediatric OCD and further suggest that paroxetine treatment may be paralleled by a reduction in

278 urine and pyrimidine metabolisms for chronic paroxetine treatment response in the mouse was further c

279 Moreover, paroxetine treatment resulted in statistically significa

280 Paroxetine treatment was significantly superior to place

281 After paroxetine treatment, the patients with depression exhib

282 greater than during RA for both placebo and paroxetine treatments (p = 0.006).

283 e compared the interaction of fluoxetine and paroxetine, two selective serotonin reuptake inhibitors

284 ere taking 20 mg/day of either fluoxetine or paroxetine underwent placebo substitution for 3 days.

285 Some study subjects received paroxetine, up to 50 mg daily, augmented by lithium carb

286 R, 1.17; 95% CI, 1.05 to 1.30; P = .01), and paroxetine use (RR, 1.29; 95% CI, 1.08 to 1.54; P = .01)

287 Youth paroxetine use also significantly increased during the p

288 oncerns about a possible association between paroxetine use and right ventricular outflow tract obstr

289 study results) of the newer antidepressants paroxetine, venlafaxine, fluoxetine, and sertraline decr

290 : prewarning (May 1, 2002 to June 19, 2003), paroxetine warning (June 20, 2003 to October 15, 2004),

291 ference in trends between the prewarning and paroxetine warning periods was significant (P < .001).

292 1) before significantly declining during the paroxetine warning study period (-44.2% per year; P < .0

293 ng the follow-up year, psychotherapy but not paroxetine was associated with a significant reduction i

294 Paroxetine was beneficial when treatment was initiated b

295 Paroxetine was effective for both men and women.

296 The selective serotonin reuptake inhibitor, paroxetine, was previously identified as a GRK2 inhibito

297 hibitors (SSRIs) fluoxetine, sertraline, and paroxetine were also absent or severely attenuated in th

298 Both psychotherapy and paroxetine were superior to treatment as usual in improv

299 Both doses of paroxetine were well tolerated.

300 However, desipramine was superior to paroxetine with respect to study retention and alcohol u